Financial Performance - The company's revenue for Q1 2023 was CNY 208,518,007.07, representing a 51.34% increase compared to CNY 137,783,337.47 in the same period last year[4] - Net profit attributable to shareholders was CNY 45,736,044.33, an increase of 80.54% from CNY 25,333,345.87 year-on-year[4] - Basic earnings per share rose to CNY 0.2017, up 80.57% from CNY 0.1117 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached ¥208,518,007.07, a significant increase of 51.2% compared to ¥137,783,337.47 in Q1 2022[16] - Net profit for Q1 2023 was ¥45,625,876.61, representing a 80.9% increase from ¥25,205,287.60 in Q1 2022[17] - Earnings per share (EPS) for Q1 2023 was ¥0.2017, compared to ¥0.1117 in the same period last year, reflecting a 80.5% increase[18] - The total comprehensive income for Q1 2023 was ¥45,625,876.61, compared to ¥25,205,287.60 in Q1 2022, showing a strong growth trajectory[18] Cash Flow - The net cash flow from operating activities reached CNY 51,288,202.98, a significant improvement from a negative CNY 5,378,157.74 in the previous year, marking a 1,053.64% increase[4] - Cash inflow from operating activities totaled ¥258,633,808.51, an increase from ¥182,856,172.52 in Q1 2022[19] - The net cash flow from operating activities for Q1 2023 was ¥51,288,202.98, compared to a negative cash flow of ¥5,378,157.74 in the same period last year[20] - The net cash flow from investing activities was negative at ¥81,871,610.61, a decrease from the previous year's negative cash flow of ¥56,440,030.96[20] - The net cash flow from financing activities was positive at ¥47,169,380.45, down from ¥162,125,824.98 in Q1 2022[20] - The net increase in cash and cash equivalents for Q1 2023 was ¥16,585,972.82, compared to an increase of ¥100,307,636.28 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,656,276,378.90, a 3.13% increase from CNY 2,575,733,822.26 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to ¥2,656,276,378.90, up from ¥2,575,733,822.26 at the beginning of the year, indicating a growth of about 3.1%[14] - Total liabilities decreased from ¥229,755,503.63 to ¥211,557,179.25, a reduction of approximately 7.9%[14] - Total liabilities increased to ¥743,116,795.21 from ¥708,199,697.29, reflecting a growth of 4.9% year-over-year[17] - Total equity attributable to shareholders reached ¥1,886,545,110.45, up from ¥1,840,809,066.12, marking a growth of 2.5%[17] Operating Costs and Income - The company reported a 54.51% increase in operating costs, totaling CNY 121,477,101.04, primarily due to increased sales volume[6] - Operating costs amounted to ¥155,644,988.93, up 42.3% from ¥109,391,163.31 in the previous year, with operating costs per revenue decreasing[16] - Other income increased by 42.48% to CNY 2,634,046.04, mainly due to higher government subsidies received[7] - The company reported a significant increase in other income to ¥2,634,046.04 from ¥1,848,731.39, indicating improved financial performance[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,140[9] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of shares, totaling 147,987,000 shares[9] - The company has no preferred shareholders as of the reporting period[11] Research and Development - Research and development expenses were ¥10,819,588.91, slightly up from ¥10,460,066.69 in the previous year, indicating continued investment in innovation[16] Other Information - The company has initiated a share acquisition plan as of January 10, 2023, and a non-public stock issuance plan on March 30, 2023[11] - The first phase employee stock ownership plan holds 820,890 shares, representing a small portion of the total shares[10] - The company did not conduct an audit for the Q1 2023 report[21] - The report was presented by the board of directors on April 24, 2023[22]

深圳市卫光生物制品股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）2022 年年度报告已于 2023 年 4 月 26 日刊登于巨潮资讯网(www.cninfo.com.cn)。为便于广大投资者更 加全面深入地了解公司 2022 年度经营业绩、发展战略等情况，公司拟于 2023 年 5 月 16 日（星期二）举办业绩说明会。具体情况如下： 一、网上业绩说明会的安排 证券代码:002880 证券简称:卫光生物 公告编号:2023-023 （一）会议召开时间：2023 年 5 月 16 日（星期二）15:00-17:00 （二）会议召开方式：网络互动方式 （三）会议召开网址：价值在线(www.ir-online.cn) （四）出席本次业绩说明会的人员：公司董事长、董事会秘书（代行）张战 先生；董事、总经理郭采平女士；董事、财务总监岳章标先生；独立董事王艳梅 女士。 二、征集问题事项及投资者参加方式 投资者可于2023年5月16日15:00-17:00通过网址h ...

Group 1: Company Overview and Competitive Advantages - The company ranks among the industry leaders in average plasma collection volume per station in 2021, with a high blood plasma utilization rate and strong operational capabilities [2] - In 2022, the company signed a cooperation agreement with the Russian government for the production and technology transfer of human blood albumin and intravenous immunoglobulin [2] - The company is focused on building the "Weiguang" brand, which has gained market recognition for its product quality [2] - The Weiguang Life Science Park aims to establish a diversified biopharmaceutical platform, targeting the global forefront of biotechnology [3] Group 2: Weiguang Life Science Park Development - The park is positioned to leverage the Greater Bay Area and Shenzhen's dual-zone drive, focusing on synthetic biology and neuroscience as key areas [3] - It aims to create a research economic ecosystem characterized by innovation incubation and achievement transformation [3] - The park will support the growth of innovative projects and establish a health ecosystem by linking industry resources [3] Group 3: Product Pricing and Production Capacity - The company maintains stable factory prices for its main products, such as human blood albumin and intravenous immunoglobulin, with minimal fluctuations [3] - Following a technological transformation of production lines in 2022, the company has seen a slight increase in plasma collection volume in the first half of 2022 [3] - The Pingguo plasma station, located in Guangxi, has achieved leading industry collection volumes due to effective local donor engagement strategies [3] Group 4: Future Plans and Expansion - The Ankang plasma station will commence operations as soon as it obtains the necessary licenses [3] - The company has plans to establish new plasma stations during the 14th Five-Year Plan period [3]

Group 1: Financial Performance - The company's blood product business achieved revenue of 8.21 billion yuan, representing a growth of 19.41% compared to the previous year [1][2] - The net profit attributable to shareholders was 1.71 billion yuan, reflecting a year-on-year increase of 9.39% [2] - The company expects a 5% increase in plasma collection volume in 2020, targeting a total of 420 tons [7] Group 2: Growth Factors - The company maintained a 100% qualification rate for batch approvals [2] - Plasma collection volume increased by approximately 6% in 2019, with the company’s plasma stations having a leading average collection capacity in the industry [2] - The marketing center strategically adjusted customer structure, optimizing distributor channels and actively exploring overseas markets [2] Group 3: Development Advantages - The company benefits from its location in Shenzhen, within the "Guangdong-Hong Kong-Macao Greater Bay Area" and "Pilot Demonstration Zone" [3] - With over 30 years of experience in the blood product industry, the company has a significant competitive edge [3] - The first major shareholder is the Guangming District State-owned Assets Supervision and Administration Commission, enhancing investor confidence [3] Group 4: Strategic Planning - Future strategies include expanding the main business, increasing production scale, and enhancing product quality [3] - The company plans to utilize the public platform for mergers and acquisitions to broaden its business scope [3] Group 5: Impact of COVID-19 - The demand for blood products, especially immunoglobulin, has significantly increased due to the pandemic [2] - The company’s plasma stations resumed operations in early March 2020, with stable annual plasma collection expected [4] Group 6: Challenges and Solutions - The company faces lower net and gross profit margins compared to peers due to market factors and rising production costs [5] - Marketing reforms in 2019 included structural adjustments and establishing key sales areas, yielding positive results [5] Group 7: Research and Development - Ongoing projects include human fibrinogen and human prothrombin complex, with clinical trials and regulatory submissions planned for 2020 [6]

证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 编号：2020-002 | --- | --- | --- | --- | |------------------------|-------------------------|--------------------------------------------|-------------------------------------------------------| | | | | | | | □ | | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ | 媒体采访 √业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 | | | 会议名称 | 卫光生物 2019 | | 年度业绩说明会 | | 参与单位名称及人员姓名 | 参与公司 2019 | | 年度业绩网上说明会的投资者 | | 时间 | 2020 年 3 月 12 | | 日 15:00-17:00 | | | | | | | | | | 全 景 网 " 全 景 • 路 演 天 下 " 投 资 者 ...

投资者来访接待活动记录表 证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|------------------------------------|-------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | √ 业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 参与公司 2018 | 年度业绩网上说明会的投资者 | | 时间 | 2019 年 4 月 18 | 日 15:00-17:00 | | 地点 | | 全 景 网 " 全 景 • 路 演 天 下 " 投 资 者 互 动 平 台 | | | （ http://rs. p5w.net | ） | | | | （本次业绩说明会采用网络远程方式举行） | | ...

投资者来访接待活动记录表 文件编号：ZJ17（ZD)R04 证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|-----------------------------|----------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | √ 业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 参与公司 2017 | 年度业绩网上说明会的投资者 | | 时间 | 2018 年 4 月 3 日 | 15:00-17:00 | | 地点 | （ http://rs. p5w.net | 全 景 网 " 全 景 • 路 演 天 下 " 投 资 者 互 动 平 台 ） | | | | （本次业绩说明会采用网络远程方式举行） ...

Group 1: Financial Performance - The main reason for the decline in gross profit margin in 2017 was due to the implementation of the "two-invoice system" and the rising cost of raw plasma, leading to increased direct material costs [2][3] - The company collected a total of 342.41 tons of plasma in 2017, with an expectation to maintain the average growth rate of plasma collection in 2018 [3][4] Group 2: Market Trends - The price trend for domestic and imported human immunoglobulin is expected to show a slight decline in the future due to increased production capacity [3] - The average usage of immunoglobulin in China is significantly lower than in developed countries, indicating substantial market potential [3] Group 3: Accounts Receivable - The increase in accounts receivable at year-end was primarily due to sales on credit to long-term cooperative customers, with most receivables aged within three months and expected to be collected within six months [3][4] Group 4: Product Development and Marketing - The company successfully launched the allergen immunoglobulin product (brand name: Min Er Kang), which has good market prospects [4][5] - The sales team currently consists of over 20 members, with plans to strengthen the sales force and adjust marketing strategies in response to the "two-invoice system" [4][5] Group 5: Future Strategies - The company plans to establish an external development platform to achieve growth through mergers, acquisitions, and collaborative operations based on market conditions [5]